Click here to read more Quest articles. print | Print this page
From the Winter 2019 Quest
After a patient’s biopsy, a pathologist examines the tissue specimen to see whether any abnormal growth is benign or malignant. However, errors in identifying the tissue’s characteristics can occur. A current area of scientific exploration concerns whether using new technologies, such as machine learning and artificial intelligence (AI), to analyze pathology slides could increase a pathologist’s accuracy and efficiency.

At this time, AI technology is not ready for clinical use. A number of people are working to improve the technology and assess its applicability in scientific studies.

However, the U.S. Food and Drug Administration (FDA) has granted the company Paige.AI a Breakthrough Device Designation. The designation is granted for technologies that have the potential to improve diagnostics or treatment for diseases such as cancer.

Paige.AI is developing machine learning algorithms to review digitized pathology slides and identify characteristics of benign and malignant tissue. Although the applications could be applied to all cancers, the company is starting with prostate cancer.


Close this window